Chime Biologics, a leading global CDMO that enables its partners' success in biologics, today announced its continued ...
Zacks.com on MSN23h
IONS’ Better-Than-Expected Q4 ResultsEC approves MRK's Welireg for two indications. FDA grants priority review to SNY and REGN's Dupixent sBLA for bullous pemphigoid.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback